Mylan, Schering-Plough settle patent suit for allergy medication
PITTSBURGH Mylan has settled patent litigation related to a generic version of Schering-Plough’s Clarinex allergy medication, the Pittsburgh-based generic drug maker announced Wednesday.
Under the settlement of the case, in the U.S. District Court of New Jersey, Mylan will have the right to market desloratadine tablets in the 5 mg strength in the United States starting July 1, 2012 or earlier, depending on certain circumstances, provided the Food and Drug Administration approves Mylan’s regulatory application. Depending on the status of Clarinex at that time, Mylan’s version may be a prescription or OTC drug.
Clarinex had sales of about $284 million in 2008, according to IMS Health data.
New antidepressant drug now available in the United States
BRIDGEWATER, N.J. A new therapy for treating major depressive disorder in adults has become available in the United States, the drug’s manufacturer announced Tuesday.
Sanofi-Aventis U.S. said that Aplenzin (bupropion hydrobromide) extended-release tablets differed from other branded and generic bupropion antidepressants because it provides a unique HBr salt extended-release formulation.
“For patients who show little clinical improvement on lower doses of bupropion, there is a need to take higher doses to treat major depressive disorder,” Duke University Medical Center consulting professor of psychiatry and behavioral sciences Prakash Masand said in a statement. “Aplenzin offers patients and physicians an alternative option which only requires one tablet, once a day at the highest bupropion dose. This provides a simple, convenient option for patients that currently need to take two to three tablets daily.”
The Food and Drug Administration originally approved the drug in April 2008. Sanofi licensed the drug from Biovail Corp. in December and markets it in the United States, including Puerto Rico.
The ASA, MedicAlert join forces to create 24-hour protection system for patients with autism, related illnesses
TURLOCK, Calif. The Autism Society of America and MedicAlert will collaborate to create a 24-hour protection system for people with autism-related illnesses and their families.
The ASA and MedicAlert said Tuesday that they would offer the system through the MedicAlert + Safe and Sound program.
“We are delighted by our new relationship with ASA,” MedicAlert president and CEO Martin Kabat said. “MedicAlert was originally founded to protect children in times of medical emergencies, and we believe this program goes right to the heart of our mission and history.”
Each person enrolled in the program will be given a personalized medical ID and wallet card to provide identification information, details on critical medical conditions and life-threatening allergies for emergency responders.